Merck halts nemtabrutinib development and ends Phase 3 BELLWAVE program
FROM THE WIRE · FINANCE.YAHOO.COM
Merck (NYSE:MRK) has halted clinical development of its blood cancer drug candidate nemtabrutinib after a recent internal review. The decision ends all Phase 3 BELLWAVE program studies after data indicated the benefit to risk profile did not justify continuation. This move…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishEnding a late-stage hematology asset reduces Merck's oncology pipeline without an immediate revenue impact.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Merck has halted clinical development of the drug nemtabrutinib.
- 02The decision follows an internal review and ends all Phase 3 BELLWAVE studies.
- 03Data indicated the benefit-to-risk profile did not justify continuation.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets